The molecular mechanisms that regulate Schwann cell (SC) plasticity and the role of the Nrg1/ ErbB-induced MEK1/ERK1/2 signalling pathway in SC dedifferentiation or in myelination remain unclear. It is currently believed that different levels of MEK1/ERK1/2 activation define the state of SC differentiation. Thus, the identification of new regulators of MEK1/ERK1/2 signalling could help to decipher the context-specific aspects driving the effects of this pathway on SC plasticity.
. It was first described as an inner ear protein and genetic mutations lead to non-syndromic hearing loss (Abe, Usami, & Nakamura, 2003) . The biological roles played by KIAA1199 only start to be elucidated. Indeed, KIAA1199 limits cell death, at least by promoting EGFR and other ErbB receptors stability and signalling (Shostak et al., 2014) . KIAA1199 is a pro-survival protein by causing glycogen breakdown as a glycogen phosphorylase kinase b-subunit (PHKB)-binding protein (Terashima et al., 2014) . KIAA1199 promotes EGF-dependent cell invasion through MEK1/ERK1/2 signalling and appears to mediate endoplasmic reticulum calcium leakage through protein kinase C alpha activation, essential for cell motility (Evensen et al., 2013) . Besides, KIAA1199 also promotes hyaluronan depolymerization in skin fibroblasts (Yoshida et al., 2013) . As such, KIAA1199, whose expression is elevated in the hippocampus and cerebellum, plays an important role in memory function in the central nervous system (Yoshino et al., 2017) .
Since KIAA1199 promotes ErbB signalling, a key pathway for SC development and plasticity, we postulated that KIAA1199 could be necessary for these SC features. To test this hypothesis, we depleted KIAA1199 in the SC-derived MSC80 cell line with RNA-interferencebased strategy and also generated inducible and conditional mouse models in which KIAA1199 is inactivated through homologous recombination, using the Cre-lox technology. We found that if KIAA1199 is dispensable for the formation and the maintenance of the myelin in adult mice, it favors myelin breakdown after injury and maintains SC in a dedifferentiated state. Moreover, we showed that KIAA1199 deficiency in SC facilitates myelination in DRG explants and remyelination after injury, but also transiently accelerates myelination at early postnatal period. Finally, our data provide evidence that KIAA1199 is necessary for Nrg1-dependent MEK1/ERK1/2 phosphorylation. Our results identify KIAA1199 as a modulator of SC dedifferentiation, via a negative regulation of myelination, and suggest that it acts through MEK1/ERK1/2 signalling.
| MATERIALS A ND METHODS

| Animals
The KIAA1199 gene (Ensembl gene ID, mouse ENSMUSG000000 52353) is located on chromosome 7. KIAA1199 exon 2 harbors the translation initiation codon. The targeting vector was generated using BAC clones from the C57BL/6J RPCIB-731 BAC library (clones RP23-41L13, RP23-276P3 and RP23-1M8) and transfected into the C57BL/6N Tac ES cell line (Taconic). Exons 3 and 4 were flanked by loxP sites. Positive selection markers have been flanked by FRT (Neomycin resistance-NeoR) and F3 (Puromycin resistance-PuroR) sites and have been inserted into intron 2 and intron 4, respectively. Homologous recombinant clones were isolated using double positive (NeoR and PuroR) selection. Mutant KIAA1199 mice were generated by Taconic. In brief, E3.5 blastocysts from superovulated BALB/c females were injected with targeted C57BL/6 ES cells and transferred to pseudopregnant NMR1 females. Chimerism was determined according to the black/white coat color, which reflects the contribution of ES cells to the BALB/c host. Highly chimeric mice were bred to C57BL/6 females and germline transmission was identified by C57BL/6 (black) and PLP 1/1 KIAA1199 loxp/loxp littermates were used as controls.
| Nerve injury
Adult cKO mice were anesthetized by intraperitoneal injection of ketamine (75 mg/kg, Bayer HealthCare) and xylazine (10 mg/kg, Pfizer).
Muscles of the right hind paw were carefully separated to expose sciatic nerves. For remyelination and functional recovery analysis, crushes were performed at the sciatic notch in order to allow regeneration. For myelin sheath breakdown analysis, nerves were axotomized at the sciatic notch and the proximal stump was pulled aside to favor SC dedifferentiation.
| Functional recovery tests
Sensory-motor coordination was assessed using mouse footprints to calculate the sciatic functional index. Mice were allowed to walk down a 60 cm long corridor lined with graph paper after inking their hind paws. For each animal, at least 3 footprints were obtained for each paw at every time point. The sciatic functional index was calculated as described previously (Inserra, Bloch, & Terris, 1998) . Motor function was analyzed by the toe-spreading reflex (Siconolfi & Seeds, 2001 ).
Sensory function was assessed by Von Frey Hair analysis (Vogelaar et al., 2004) . (Chaballe et al., 2011) . After careful dissection, nerves were left for 2 weeks in pro-degeneration medium: DMEM, 10% FBS, fungizone (2.5 mg/mL, ThermoScientific), forskolin (2 mM, Calbiochem), gentamycine (ThermoScientific) and Heregulin-b1 (Nrg1) (10 ng/mL, R&D Systems) at 378C, 5% CO 2 . After enzymatic (3 h in 0.3 mg/mL collagenase I and 2.5 mg/mL dispase II in Leibovitz medium) and mechanical dissociations, cells were plated on pre-coated poly-Llysine (50 lg/mL, Sigma-Aldrich) and laminin (20 lg/mL, Sigma-Aldrich) culture dishes and incubated at 378C, 5% CO 2 in N2 HRG medium: 50% DMEM 50% F12 supplemented with N2 (ThermoScientific), gentamycin (50 lg/mL), fungizone (2.5 lg/mL), forskolin (2 lM), and Nrg1 (10 ng/mL). A few days before confluence, inactivation of KIAA1199 was induced by the addition of 1 lM 4-OH TM (Sigma-Aldrich) for 2 days in the medium of all cultures.
| Lentiviral infections
The control or shRNAs targeting KIAA1199 were purchased from Sigma-Aldrich. Lentiviral infections in MSC80 cells were performed as previously described (Creppe et al., 2009 After 1 week in Neurobasal medium supplemented with 2 mM Glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, B27 supplement (ThermoFisher), 50 ng/mL NGF (Merck Millipore), SCs were aligned along the axons. For KIAA1199 inactivation, cultures were treated with 1 lM 4-OH TM for 2 days in the Neurobasal medium just before switching to myelination medium (DMEM, N2 supplement, 50 ng/mL NGF, 2.5% horse serum (ThermoScientific), 20 lg/mL BPE (ThermoFisher), 0.5 lM forskolin, 100 U/mL penicillin, 100 U/mL streptomycin) supplemented with 50 lg/mL of freshly dissolved ascorbic acid (Sigma-Aldrich) to induce basal lamina formation and myelination. After 2 weeks of replacing 70% of the medium every 2 days, cultures were fixed with 4% paraformaldehyde and processed for immunochemistry (He et al., 2010) . The number of MBP-positive segments/field was quantified (3-5 fields/well, 4-6 wells/embryo, 9-12 embryos out of 3 independent cultures).
| Electron microscopy
Mice were perfused with a solution containing 2.5% glutaraldehyde in 0.1 M cacodylate buffer pH 7.2. Sciatic nerves were harvested and postfixed with this solution for 2 h at 48C, washed twice in 0.1 M cacodylate buffer, and postfixed with 1% osmium in PO 4 buffer for 30 min at 48C. Sciatic nerves were progressively dehydrated in successive ethanol baths and then soaked in epoxypropane twice during 10 min.
Tissues were embedded in epon resin by soaking in a mixture of epoxypropane/epon in proportions 2:1, then 1:1 and finally 1:2, for 1, 2, and 3 h, respectively. Sciatic nerves were then soaked in epon resin overnight before hardening the resin at 608C for 2 days. The blocks were trimmed, and semi-thin (1 lm) and ultra-thin (75 nm) crosssections were cut with a microtome. Semi-thin sections were collected onto glass slides, and dried on a hot plate before staining with 0.5% toluidine blue. Ultra-thin sections were contrasted with 5% uranyleacetate and lead citrate. 
| Western blotting
Cells or sciatic nerves were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP40, 0.1% sodium deoxycholate, 1 mM EDTA, 1 mM NaF, 10 mM Na 3 VO 4 , and proteases inhibitors). Cellular extracts were cleared by centrifugation (10,000g) for 10 min at 48C and 5-50 lg of proteins were separated by SDS-PAGE and transferred to 0.45 lm nitrocellulose membranes (GE Healthcare).
Membranes were blocked for 1 h in 5% non-fat milk PBS-0.1% Tween 20 and incubated overnight at 48C with specific primary antibodies followed by incubation with HRP-conjugated secondary antibodies for 2 h at room temperature (HRP-conjugated anti-mouse, anti-rabbit 1:10,000, GE Healthcare). Membranes were developed using ECL reagent (Thermo Scientific). The following antibodies were used: home- 
| RNA extraction and real-time PCR
Total RNAs from MSC80 cells and primary SCs were extracted using the Rneasy Mini kit (Qiagen) according to manufacturer's instructions.
cDNAs were synthesized using the Revert Aid H Minus First Strand cDNA Synthesis kit (Fermentas). Subsequent PCRs were performed using the Power SYBR Green PCR Master kit (Takara Bio Inc.) on the LightCycler 480 (Roche). The mRNA level was expressed relative to the mean of all control samples and normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ( Table 1) .
| RNA sequencing
Total RNAs from MSC80 cells (control or KIAA1199 depleted, n 5 5)
were extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's protocol. Library preparation and sequencing were performed at the GIGA Genomics facility (University of Liège, Belgium).
RNA integrity was verified on the Bioanalyser 2100 with RNA 6000
Nano chips, and RIN scores were >9 for all samples. The Illumina TruSeq® Stranded mRNA was used to prepare libraries from 500 ng total
RNAs. PolyA RNAs were purified with polyT-coated magnetic beads, chemically fragmented, and used as template for cDNA synthesis using random hexamers. cDNA ends were subsequently end-blunted, adenylated at 3 0 OH extremities, and ligated to indexed adaptors. Finally, the adapters ligated library fragments were enriched by PCR following Illumina's protocol and purified with Ampure XP magnetic beads. Libraries were validated on the Bioanalyser DNA 1000 chip and quantified by 
| Statistical analysis
Data are plotted as mean values 6 standard errors of mean (SEM). Statistics for dual comparisons were generated using unpaired Student's ttests, and statistics for multiple comparisons were generated using one-way ANOVA or two-way ANOVA followed by Dunnet's and Sidak's post hoc tests (GraphPad Prism software); *: p < 0.05, **:
p < 0.01, ***: p < 0.001 for all statistics herein.
| R E S U LTS
| Model validation
To investigate the role of KIAA1199 in SCs, we generated a mouse We also crossed the KIAA1199 floxed mouse with another transgenic mouse in which the Cre recombinase expression is under the control of the desert hedgehog (DHH) promoter (5 cKO mouse) (Figure 1e) . The Cre-driven recombination efficiency was demonstrated in primary SC cultures in both real-time PCR and WB analyses ( Figure 1f and g, respectively). Even though KIAA1199 protein expression is decreased in the cKO primary SCs compared to WT, it should be pointed out that the protein is still present at about 50% (Figure 1g ).
When we assessed the Cre recombination by immunostaining against YFP on sciatic nerve sections from adult mice, it appeared that not all SCs express the YFP, demonstrating that the recombination is not 100% effective (Figure 1h ). 
| KIAA1199 is necessary for SC dedifferentiation
To further evaluate the role of KIAA1199 in SC dedifferentiation, we took advantage of our inducible and conditional knockout mouse model (iKO) to perform in vitro and ex vivo assays to assess myelin breakdown. First, we cultured myelinating SCs isolated from postnatal day 9 (P9) WT and PLP CreERT/1 KIAA1199 loxp/loxp nerves (Cre-recombination assessed via anti-YFP immunostaining as illustrated on Figure   3a ) and analyzed the disappearance of myelin basic protein (MBP) by double immunofluorescent cytochemistry against S100 and MBP (as illustrated on Figure 3b ) over a 10 days period of time. We showed that KIAA1199-invalidated cultures contain significantly more MBP positive SCs after 10 days compared to WT cultures, respectively 81.20% 6 4.50 and 46.22%6 10.60 (Figure 3c ). This tendency was supported by EM analysis of the myelin sheath fragmentation of nerve explants after 4 days in pro-degeneration medium. The number of intact myelin sheaths was higher in PLP CreERT/1 KIAA1199 loxp/loxp nerves (12.10 6 0.81) compared to WT (9.61 6 0.81) (Figure 3d and e).
Therefore, myelin clearance is significantly less effective when KIAA1199 is inactivated.
Because KIAA1199 deficiency in SCs was shown to promote a shift of the transcriptional expression program toward differentiating SCs, we investigated whether the myelination process could be influenced by pro-myelinating signals. To address this issue, we cultured DRG explants from E13.5 PLP CreERT/1 KIAA1199 loxp/loxp and WT mice and let the dedifferentiated SCs migrate along the growing neurites before adding 4-OH TM to inactivate KIAA1199. We then induced myelination with fresh ascorbic acid-containing medium. After two weeks, the co-cultures were fixed and processed for double anti-MBP and anti-bIII tubulin immunofluorescent stainings (Figure 3f ). We However, at P7, the mean g ratio calculated for over 500 fibers from both WT and cKO nerves was significantly lower in cKO mice (g ratio 5 0.666 6 0.0007) compared to WT mice (g ratio 5 0.695 6 0.005), revealing an acceleration of myelination in the absence of KIAA1199 in SCs (Figure 4b-f) . In adult mice, no obvious abnormalities were noticed in the overall nerve architecture of cKO animals, as assessed by morphological examinations (Figure 4b-f) . The myelin sheath thickness was also evaluated by EM analysis and no statistical difference was observed in the mean g ratios of WT (g ratio 5 0.71 6 0.01) and cKO (g ratio 5 0.72 6 0.01) animals ( Figure 4d ). The numbers of myelinated and unmyelinated fibers was also similar (data not shown). Therefore, KIAA1199 is dispensable for myelination but its absence transiently accelerates myelination. KIAA1199 could thus be considered as a novel negative regulator of myelination.
| KIAA1199 is required for SC myelin breakdown after injury and its inactivation facilitates remyelination
Because KIAA1199 promotes SC dedifferentiation and myelin clearance, two essential events taking place after injury, we investigated with 4-OH TM, serum starved and stimulated with Nrg1 (10 ng/mL) for 10 min. WB on the resulting cell extracts revealed a decreased phosphorylation of MEK and ERK when KIAA1199 is decreased. Data are expressed as mean 6 SEM. Statistics: (b) one-way ANOVA followed by Dunnett's post-hoc analysis, n 5 3 in all groups for each qPCR; * p < 0.05, ** p < 0.01, *** p < 0.001 KIAA1199 functions following nerve injury. We performed nerve axotomy in which the proximal stump was pulled aside to prevent regeneration and favor SC dedifferentiation. Three days later, EM analysis of myelin sheath fragmentation 3 mm from the injured site revealed a significant higher number of intact myelin sheaths in the cKO nerves (15.60 6 0.51/1000 lm 2 ) compared to WT (13.65 6 0.50/1000 lm 2 ), indicating a role for KIAA1199 in myelin degradation after injury (Figure 5a and b) .
To investigate whether KIAA1199 inactivation in SCs would impact remyelination and functional recovery following injury, we crushed the sciatic nerves of WT and cKO animals in order to allow axon regeneration. The myelin sheath thickness was assessed on electron micrographs of WT and cKO nerves 2 months after crush (Figure 5c ). We found a smaller mean g ratio in cKO nerves (0.727 6 0.006) compared to WT (0.754 6 0.005), pointing out a significant increased myelin thickness when KIAA1199 is decreased (Figure 5d ). The scatter plot of g ratio versus axon diameter indicated that the myelin thickness is particularly increased for the smallest axons and that the overall distribution of myelinated fibers is unaffected when KIAA1199 is decreased 3.6 | KIAA1199 is required for Nrg1-signalling and MEK1/ERK1/2 phosphorylation
To gain more information about molecular mechanisms by which KIAA1199 acts on SC dedifferentiation, we profiled the transcriptome of control and KIAA1199-depleted MSC80 cells to identify pathways specifically deregulated upon KIAA1199 depletion. Total RNAs were extracted and subjected to high throughput RNA sequencing. Interestingly, a gene set enrichment analysis (GSEA) highlighted a significant and specific Nrg1-dependent signature that was decreased in KIA1199-depleted cells ( Figure   6a ). Real-Time PCR analysis confirmed that selected Nrg1 target mRNAs (Topilko et al., 1997; Mercier, Turque, & Schumacher, 2001; Amin, Tuck, & Stern, 2005; Gao, Daugherty, & Tourtellotte, 2007; Nagashima et al., 2007; Woodhoo et al., 2009; Ji et al., 2012; Adams et al., 2017) were down regulated in KIAA1199-depleted MSC80 cells (Figure 6b ).
Given the fact that Nrg1 has been suggested as the potential signal driving SC dedifferentiation through Raf/MEK1/ERK1/2 signalling (Napoli et al., 2012) , we analyzed whether KIAA1199 deficiency would impair this pathway. To test this, we serum-starved and stimulated or not control or KIAA1199-depleted MSC80 cells with Nrg1 (10 ng/mL) for different periods of time. WB analysis demonstrated a decreased expression of ErbB3 and a delay in the phosphorylation of both MEK1
and ERK1/2 (Figure 6c ). We also cultured primary SCs from WT and iKO mice and treated them for 2 days with 4-OH TM to induce recombination, then serum starved and stimulated with Nrg1 for 10 minutes.
The WB analyses again revealed a decreased phosphorylation of both MEK1 and ERK1/2 when KIAA1199 is decreased (Figure 6d ). Therefore, KIAA1199 promotes Ngr1-dependent MEK1 and ERK1/2 activation in SCs.
| DISCUSSION
Nerve regeneration involves complex multicellular and molecular events in which SCs play a role of orchestrator (Cattin & Lloyd, 2016) .
The signal that induces this pro-healing response remains unknown but originates from damaged nerves and instructs SCs to reprogram into specialized repair cells, named "transdifferentiated" cells (Arthur-Farraj et al., 2012) . The remarkable ability of SCs to dedifferentiate has been extensively studied but the molecular mechanisms that modulate their plasticity only start to be elucidated (Boerboom, Dion, Chariot, & Franzen, 2017) . Whereas the role of cJun or Notch as key players for SC reprogramming is well established, the function of some pathways including Nrg1/ErbB and MEK1/ERK1/2 signalling remains unclear.
Indeed, these pathways have been demonstrated to regulate both SC differentiation and plasticity depending on their quantitative and temporal activation. In one hand, the ectopic activation of Raf in cultured differentiated SCs drives their dedifferentiation even in co-cultures with DRG-neurons (Harrisingh et al., 2004) . More recently, Napoli et al. (2012) revealed that a Tamoxifen-inducible Raf transgene in SCs is sufficient to provoke the down-regulation of myelin proteins and the expression of dedifferentiation markers in vivo, even in the absence of axonal damage. On the other hand, different studies showed that ERK1/2 activation is actually a pro-myelinating signal and that its inhibition blocks SC differentiation and myelination in vivo (Grossmann et al., 2009; He et al., 2010; Newbern et al., 2011) . The reconciling hypothesis could be that different levels of ERK1/2 activation would define the state of SC differentiation. Low or basal ERK1/2 activity would induce SC myelination while high ERK1/2 levels would drive their dedifferentiation (Newbern & Snider, 2012 (Parkinson et al., 2008) . Moreover, the inactivation of Notch signalling in vivo leads to premature myelin formation and the loss of DDIT4 expression both in vitro and in vivo results in sustained hypermyelination (Woodhoo et al., 2009; Noseda et al., 2013) .
Consistently with a role of KIAA1199 in Nrg1-dependent ErbB and MEK1/ERK1/2 signallings, we expected some defects in SC myelination in the absence of KIAA1199 in mice. Indeed, several studies showed that those pathways control both the development of SCs and the myelination program (Britsch et al., 1998; Woldeyesus et al., 1999; Garratt, Britsch, & Birchmeier, 2000; Birchmeier & Nave, 2008; Grossmann et al., 2009; Newbern & Birchmeier, 2010; Newbern et al., 2011) . Using a mouse model in which KIAA1199 is inactivated in SCs at E12, we indeed show a transient acceleration of myelination at P7, without any defects in the radial sorting at P0-P1. Surprisingly, the analyses of this mutant mouse at adult stage did not show any detectable defects in myelin. This could potentially be attributed to residual KIAA1199 levels in the knockout mouse but also to the complexity of in vivo systems in which compensatory mechanisms and functional overlap may hide the detection of a phenotype. Since KIAA1199 participates in the modulation of Nrg1-induced MEK1/ERK1/2 activation, its residual levels in mutant mice could be sufficient for normal SC development. Finally, in situations in which MEK1/ERK1/2 signalling is highly activated (i.e., after injury), the expression of KIAA1199 in the conditional knockout mice may be diminished enough to highlight its function.
ERK1/2 signalling is highly activated following injury and plays a key role in initiating demyelination triggered by nerve damage and other pathological conditions (Sheu, Kulhanek, & Eckenstein, 2000; Harrisingh et al., 2004; Napoli et al., 2012; Fledrich et al., 2014) . Nrg1 has been proposed to be the signal that activates MEK1/ERK1/2-induced dedifferentiation and it has been shown that the direct binding of Mycobacterium leprae on ErbB2 on SCs results in the activation of ERK1/2 signalling and demyelination (Tapinos et al., 2006; Napoli et al., 2012) . Also, the Nrg1/ErbB system is highly regulated during peripheral nerve degeneration, which further supports its role in SC plasticity (Carroll, Miller, Frohnert, Kim, & Corbett, 1997; Kwon et al., 1997; Napoli et al., 2012; Ronchi et al., 2016) . Guertin, Zhang, Mak, Alberta, and Kim (2005) showed that ErbB2 is activated in SCs after sciatic nerve injury and that its transient activation is sufficient to induce demyelination in compartmentalized cell culture chambers. They also showed that the treatment of rats with an ErbB2 inhibitor leads to a reduction of demyelination after nerve transection. Furthermore, in vitro experiments imitating nerve lesions revealed that Nrg1 treatment is beneficial for SC response to damage (Mahanthappa, Anton, & Matthew, 1996; Li, Wigley, & Hall, 1998) . However, Atanasoski et al. (2006) revealed contradictory results. They showed that the lack of ErbB2 in adult SCs does not disturb their proliferation and survival after nerve injury, despite reduced levels of phosphorylated MAPK.
Our examinations on the mutant mice after nerve injury provide evidence that KIAA1199 promotes myelin breakdown and SC dedifferentiation. Moreover, in consistency with the fact that decreased KIAA1199 expression in dedifferentiated SCs tend to boost their differentiation, we observed a small but significant increase of the myelin sheath thickness following injury in the mutant nerves. However, the functional effect of the decreased expression of KIAA1199 on SC plasticity is quite mild, as it did not disturb the overall recovery after injury.
Let's note however that some neurophysiological parameters like nerve conduction velocity remain to be investigated.
In agreement with the literature, our results strongly suggest that KIAA1199 acts in the Nrg1-induced MEK1/ERK1/2 signalling pathway to modulate SC dedifferentiation. Our data also support the findings that Nrg1/ErbB and MEK1/ERK1/2 signallings are involved in SC plasticity, which may define new therapies that specifically target SC dedifferentiation and regenerative potential to enhance repair. However, this approach should be cautioned since enhanced activation of Nrg1/ ErbB and MEK1/ERK1/2 signalling can lead to the development of nerve tumours (Frohnert, Stonecypher, & Carroll, 2003; Fallon, Havlioglu, Hamilton, Cheng, & Carroll, 2004; Harrisingh et al., 2004; Tapinos et al., 2006) . Consistently, KIAA1199 is increased in multiple solid tumours and represents a promising target to interfere with ErbB signalling in cancer (Matsuzaki et al., 2009; Kuscu et al., 2012; Tiwari et al., 2013; Shostak et al., 2014) . While this study identified 
